- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05030298
고급 신경교종 치료를 위한 수술 전 방사선 수술, 신교종 연구
높은 등급 신경교종의 수술 전 방사선 수술: I/IIA 임상 시험: NeoGlioma 연구
This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely give a single large dose of radiation to the tumor. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pre-operative radiosurgery may improve the odds of brain tumor control and reduce treatment-related side effects.
연구 개요
상태
정황
상세 설명
PRIMARY OBJECTIVE:
I. To evaluate the feasibility, safety and maximum tolerated dose (MTD) of preoperative radiosurgery in the treatment of patients with biopsy-proven high-grade glioma prior to conventional therapy.
SECONDARY OBJECTIVES:
I. Acute clinical toxicity profile using Common Terminology Criteria for Adverse Events (CTCAE) version 5 (defined as within 4 weeks of completion of postoperative radiotherapy.
II. Radiographic tumor control at 12 months following surgery (per Response Assessment in Neuro-Oncology [RANO] criteria).
III. Rate of pseudoprogression at first post radiation scan (RANO criteria). IV. Overall survival at 12 months following surgery.
CORRELATIVE RESEARCH OBJECTIVE:
I. Evaluation of the tumor repair pathways triggered by radiation, tumor vascular changes, tumor microenvironment immune profiling, cell cultures, and the creation of orthotopic xenograft models for future study.
OUTLINE: This is a dose-escalation study.
Patients undergo magnetic resonance imaging (MRI)-guided stereotactic biopsy. Within 14 days of registration, patients undergo either standard of care surgery or radiosurgery in 1 fraction. Within 14 days, patients who underwent radiosurgery then undergo surgery. Within 4-6 weeks, all patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without tumor treating fields (TTF) at the discretion of the treating neuro-oncologist. Additionally, patients undergo MRI and blood sample collection and optional biopsy throughout the study.
After completion of study treatment, patients are followed up every 2-3 months for 12 months and then every 3 months for up to 3 years after registration.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
연구 장소
-
-
Arizona
-
Phoenix, Arizona, 미국, 85054
- 모병
- Mayo Clinic in Arizona
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Sujay Vora, MD
-
-
Florida
-
Jacksonville, Florida, 미국, 32224-9980
- 모병
- Mayo Clinic in Florida
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Daniel M. Trifiletti, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age >= 18 years
- Clear clinical and radiographic evidence of primary high grade glioma (HGG) as judged by the Mayo multidisciplinary neuro-oncology team (World Health Organization [WHO] grade III-IV, including glioblastoma) regardless of IDH and MGMT status
- Patients who underwent a previous biopsy confirming high grade glioma are eligible for enrollment
- Planned neurosurgical resection of tumor
- Judged to not be at risk of significant clinical risk (i.e. herniation) with radiation-induced edema prior to resection
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- Negative pregnancy test done =< 14 days prior to registration, for women of childbearing potential only. Patients over 50 years of age who decline pregnancy testing are still eligible without a pregnancy test.
- Ability to complete questionnaire(s) by themselves or with assistance
- Provide written informed consent
- Willing to receive adjuvant radiotherapy at enrolling institution at the time of registration
- Willing to provide tissue and/or blood samples for correlative research purposes
Exclusion Criteria:
-
Any of the following:
- Pregnant women
- Nursing women who are unwilling to cease during therapy
- Men or women of childbearing potential who are unwilling to employ adequate contraception
-
Prior history of cranial radiotherapy
-
Unwillingness to participate in study
-
Investigator discretion that enrollment on the study would pose undo harm or risk to the patient
-
Non-MRI compatible implanted medical device
-
Use of systemic anti-cancer therapy within the previous 3 months
-
Medical contraindication to craniotomy and tumor resection
-
Pathologic confirmation of grade I-II glioma, brain metastasis, or other brain tumor
- Note: Patients with a history of grade I-II glioma are eligible if they have only received surgery as treatment and now there is concern for transformation to grade III-IV tumor
-
Primary spinal cord glioma or primary brainstem glioma
-
Residual tumor of excessive volume or eloquent location per investigator discretion
-
Patients who are unwilling or unable to comply with study procedures
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Treatment (stereotactic biopsy, radiosurgery, surgery)
Patients undergo MRI-guided stereotactic biopsy. Within 14 days of registration, patients undergo either standard of care surgery or radiosurgery in 1 fraction. Within 14 days, patients who underwent radiosurgery then undergo surgery. Within 4-6 weeks, all patients then receive standard of care radiation therapy over 30 fraction and temozolomide daily with or without TTF at the discretion of the treating neuro-oncologist. Additionally, patients undergo MRI and blood sample collection and optional biopsy throughout the study. |
Undergo blood sample collection
다른 이름들:
Undergo MRI
다른 이름들:
Undergo radiation therapy
다른 이름들:
Undergo surgery Undergo biopsy
다른 이름들:
Undergo radiosurgery
다른 이름들:
Undergo MRI-guided stereotactic biopsy Drug
다른 이름들:
Undergo TTF
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients experiencing any acute grade 3 or greater unplanned adverse event
기간: Up to 4 weeks postoperative radiotherapy
|
Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. The toxicity rate will be estimated using a binomial estimator and a one-sided 95% confidence interval (CI) of the rate will be computed with normal approximation. |
Up to 4 weeks postoperative radiotherapy
|
|
Acute clinical toxicity
기간: Up to 4 weeks postoperative radiotherapy
|
Assessed per CTCAE v5.0. The maximum grade for each type of acute adverse events will be recorded for each patient. Data will be summarized as frequencies and relative frequencies by treatment arm. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Rates will be compared between arms using chi-squared tests. |
Up to 4 weeks postoperative radiotherapy
|
|
Maximum tolerated dose (MTD) of preoperative radiosurgery
기간: Up to 4 weeks postoperative radiotherapy
|
After the trial is completed, the MTD will be based on isotonic regression. The dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate will be selected as the MTD. If there are ties, the higher dose level will be selected when the isotonic estimate is lower than the target toxicity rate; and the lower dose level will be selected when the isotonic estimate is greater than or equal to the target toxicity rate. |
Up to 4 weeks postoperative radiotherapy
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Radiographic tumor control
기간: At 12 months post-surgery
|
Assessed per Response Assessment in Neuro-Oncology (RANO) criteria. The cumulative incidence of radiographic tumor recurrence will be estimated using a competing risks method (Gooley et al.). The competing risks will be death. |
At 12 months post-surgery
|
|
Rate of pseudoprogression
기간: At first post radiation scan
|
Assessed per RANO criteria. Data will be summarized as frequencies and relative frequencies overall and by treatment dose. Additionally, the relationship of the pseudoprogression(s) to the study treatment will be taken into consideration. |
At first post radiation scan
|
|
Overall survival
기간: At 12 months post-surgery
|
Overall survival (OS) is defined as the time from study enrollment to death by any cause. Will be estimated with a Kaplan-Meier estimator and curve for patients treated with preoperative radiosurgery. Estimates will be given for specific time points along with 95% CIs. |
At 12 months post-surgery
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Tumor tissue evaluation of tumor changes
기간: Up to 14 days Post-radiosurgery
|
Any excess tissue recovered from the surgical specimen (after standard of care pathologic evaluation) will undergo a series of advanced testing, potentially including but not limited to evaluation of the tumor repair pathways triggered by radiation, tumor vascular changes, tumor microenvironment immune profiling, cell cultures, and the creation of orthotopic xenograft models for future study. Analysis will be completed outside the scope of this protocol. |
Up to 14 days Post-radiosurgery
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Daniel M. Trifiletti, MD, Mayo Clinic
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 신생물, 신경상피
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 신경교종
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 수술 절차, 수술
- Azoles
- 세포 학적 기술
- 세포 진단
- 물리적 현상
- 다 카르 바진
- 트리아 젠
- 이미 다졸
- 진단 기술, 수술
- 화학 기술, 분석
- 스펙트럼 분석
- 전형적인 기술
- 신경 외과 절차
- 테모졸로마이드
- 방사선 요법
- 방사
- 생검
- 시편 처리
- 자기 공명 분광법
- 방사선 수술
기타 연구 ID 번호
- MC210710
- 20-013209 (기타 식별자: Mayo Clinic Institutional Review Board)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .